TSCAN THERAPEUTICS INC (TCRX) Stock Price, Quote, News and Overview
NASDAQ:TCRX - Nasdaq - US89854M1018 - Common Stock - Currency: USD
TCRX Quote, Performance and Key Statistics
1.38
+0.02 (+1.47%)
The current stock price of TCRX is 1.38 USD. In the past month the price increased by 15%. In the past year, price decreased by -82.15%.
TCRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.07 | 328.29B | ||
| AMGN | AMGEN INC | 13.1 | 146.27B | ||
| GILD | GILEAD SCIENCES INC | 12.68 | 122.21B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 110.44B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.36 | 59.13B | ||
| ARGX | ARGENX SE - ADR | 299.54 | 34.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.61B | ||
| ONC | BEIGENE LTD-ADR | 5.88 | 25.43B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.78B | ||
| NTRA | NATERA INC | N/A | 22.10B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.31B | ||
| BIIB | BIOGEN INC | 7.48 | 17.35B |
Related stock screener links
About TCRX
Company Profile
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 194 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Company Info
TSCAN THERAPEUTICS INC
880 Winter Street
Waltham MASSACHUSETTS US
CEO: David Southwell
Employees: 182
Phone: 18573999500
TSCAN THERAPEUTICS INC / TCRX FAQ
What is the stock price of TSCAN THERAPEUTICS INC today?
The current stock price of TCRX is 1.38 USD. The price increased by 1.47% in the last trading session.
What is the ticker symbol for TSCAN THERAPEUTICS INC stock?
The exchange symbol of TSCAN THERAPEUTICS INC is TCRX and it is listed on the Nasdaq exchange.
On which exchange is TCRX stock listed?
TCRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TSCAN THERAPEUTICS INC stock?
14 analysts have analysed TCRX and the average price target is 9.01 USD. This implies a price increase of 552.9% is expected in the next year compared to the current price of 1.38. Check the TSCAN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TSCAN THERAPEUTICS INC worth?
TSCAN THERAPEUTICS INC (TCRX) has a market capitalization of 78.09M USD. This makes TCRX a Micro Cap stock.
How many employees does TSCAN THERAPEUTICS INC have?
TSCAN THERAPEUTICS INC (TCRX) currently has 182 employees.
What are the support and resistance levels for TSCAN THERAPEUTICS INC (TCRX) stock?
TSCAN THERAPEUTICS INC (TCRX) has a support level at 1.37 and a resistance level at 1.55. Check the full technical report for a detailed analysis of TCRX support and resistance levels.
Is TSCAN THERAPEUTICS INC (TCRX) expected to grow?
The Revenue of TSCAN THERAPEUTICS INC (TCRX) is expected to grow by 17.14% in the next year. Check the estimates tab for more information on the TCRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TSCAN THERAPEUTICS INC (TCRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TCRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TCRX, evaluating the profitability, health, valuation and growth aspects
- TSCAN THERAPEUTICS INC (TCRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TSCAN THERAPEUTICS INC (TCRX) Sales and EPS estimates to see what analysts future expectations are.
- TSCAN THERAPEUTICS INC (TCRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TSCAN THERAPEUTICS INC (TCRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- TSCAN THERAPEUTICS INC (TCRX) Stock Chart to make your own analysis
- TSCAN THERAPEUTICS INC (TCRX) Latest news and press-releases to stay up to date.
Does TSCAN THERAPEUTICS INC (TCRX) stock pay dividends?
TCRX does not pay a dividend.
When does TSCAN THERAPEUTICS INC (TCRX) report earnings?
TSCAN THERAPEUTICS INC (TCRX) will report earnings on 2025-05-13, before the market open.
What is the Price/Earnings (PE) ratio of TSCAN THERAPEUTICS INC (TCRX)?
TSCAN THERAPEUTICS INC (TCRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.15).
What is the Short Interest ratio of TSCAN THERAPEUTICS INC (TCRX) stock?
The outstanding short interest for TSCAN THERAPEUTICS INC (TCRX) is 3.49% of its float. Check the ownership tab for more information on the TCRX short interest.
TCRX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TCRX. When comparing the yearly performance of all stocks, TCRX is a bad performer in the overall market: 96.03% of all stocks are doing better.
TCRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TCRX. TCRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TCRX Financial Highlights
Over the last trailing twelve months TCRX reported a non-GAAP Earnings per Share(EPS) of -1.15. The EPS increased by 39.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.36% | ||
| ROE | -52.91% | ||
| Debt/Equity | 0.13 |
TCRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to TCRX. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -4.66% and a revenue growth 17.14% for TCRX